With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare

Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.

Unilever_1200x675
• Source: Shutterstock

Unilever’s unexpected pursuit of GlaxoSmithKline’s Consumer Healthcare business appears to be over, with the London-based firm confirming it would not submit a higher bid than its rejected £50bn ($68bn) cash and shares offer.

New information published by GSK since that failed bid outlining the medium-term growth prospects for Consumer Healthcare has failed to...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Europe

More from Geography